

Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A9C1473E3ABBEN.html>

Date: June 2022

Pages: 78

Price: US\$ 2,000.00 (Single User License)

ID: A9C1473E3ABBEN

Abstracts

Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly – Drugs In Development, 2022, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 7, 5, 2 and 1 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Acromegaly – Overview

Acromegaly – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly – Companies Involved in Therapeutics Development

Amolyt Pharma

Amryt Pharma Plc

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

ASCIL Biopharm

Camurus AB

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Debiopharm International SA

DexTech Medical AB

Enesi Pharma Ltd

Foresee Pharmaceuticals Co Ltd

GeneScience Pharmaceuticals Co Ltd

Genevant Sciences Ltd

GlyTech Inc

Ionis Pharmaceuticals Inc

Italfarmaco SpA

OPKO Health Inc

Pharmathen Global BV

Rani Therapeutics LLC

Strongbridge Biopharma plc

Acromegaly – Drug Profiles

atesidorsen sodium – Drug Profile

Product Description

Mechanism Of Action
History of Events
AZP-3813 – Drug Profile
Product Description
Mechanism Of Action
History of Events
cimderlirsen sodium – Drug Profile
Product Description
Mechanism Of Action
History of Events
Debio-4126 – Drug Profile
Product Description
Mechanism Of Action
FP-002 – Drug Profile
Product Description
Mechanism Of Action
GNV-705 – Drug Profile
Product Description
Mechanism Of Action
GT-02037- – Drug Profile
Product Description
Mechanism Of Action
ITF-2984 – Drug Profile
Product Description
Mechanism Of Action
History of Events
lanreotide acetate CR – Drug Profile
Product Description
Mechanism Of Action
History of Events
lanreotide SR – Drug Profile
Product Description
Mechanism Of Action
MOD-12014 – Drug Profile
Product Description
Mechanism Of Action
octreotide – Drug Profile
Product Description
Mechanism Of Action

octreotide – Drug Profile

Product Description

Mechanism Of Action

History of Events

octreotide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

octreotide acetate CR – Drug Profile

Product Description

Mechanism Of Action

History of Events

octreotide acetate DR – Drug Profile

Product Description

Mechanism Of Action

History of Events

octreotide acetate microspheres – Drug Profile

Product Description

Mechanism Of Action

octreotide LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

octreotide LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

paltusotine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Somadex – Drug Profile

Product Description

Mechanism Of Action

History of Events

veldoreotide ER – Drug Profile

Product Description

Mechanism Of Action

veldoreotide IR – Drug Profile

Product Description

Mechanism Of Action

History of Events

Acromegaly – Dormant Projects

Acromegaly – Discontinued Products

Acromegaly – Product Development Milestones

Featured News & Press Releases

Jun 14, 2022: Amryt to present data from OPTIMAL and MPOWERED phase 3 trials open label extension of Mycapssa (oral octreotide) at ENDO 2022

May 24, 2022: Amolyt Pharma announces abstracts accepted for presentation to the product AZP-3813 at ECE and ENDO

May 11, 2022: Amryt announces new patent for Mycapssa

Apr 13, 2022: Amryt Announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd year of OPTIMAL open label extension study in acromegaly patients

Jan 11, 2022: Amryt announces positive long-term safety and efficacy data confirming the role for mycapssa (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Jan 04, 2022: The Lancet Diabetes & Endocrinology publishes positive results for the MPOWERED phase 3 trial for Mycapssa (oral octreotide) in Acromegaly patients

Nov 08, 2021: Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

Jun 28, 2021: Chiasma announces submission of marketing authorization application for MYCAPSSA to the European Medicines Agency

Jun 28, 2021: Crinetics Pharmaceuticals announces dosing of first patient in phase 3 PATHFINDER-1 study evaluating oral paltusotine for the treatment of acromegaly

May 27, 2021: Chiasma presents positive patient-reported outcomes data from its MPOWERED phase 3 trial comparing MYCAPSSA to long-acting injectables for the maintenance treatment of adults with acromegaly

May 20, 2021: Chiasma to present encore and new data from MPOWERED phase 3 trial at upcoming e-ECE and AACE Virtual Conferences

May 13, 2021: Acentrus specialty contracts with Chiasma to bring MYCAPSSA (octreotide) to health systems and hospitals in the Acentrus Network

Mar 22, 2021: Chiasma presents long-term safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly at ENDO 2021

Mar 20, 2021: Chiasma presents new positive data for MYCAPSSA from phase 3 trial MPOWERED for the maintenance treatment of acromegaly at ENDO 2021

Mar 10, 2021: Chiasma to present new data from two phase 3 trials, CHIASMA
OPTIMAL and MPOWERED, at ENDO 2021

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Acromegaly, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acromegaly – Pipeline by Amolyt Pharma, 2022
Acromegaly – Pipeline by Amryt Pharma Plc, 2022
Acromegaly – Pipeline by Antisense Therapeutics Ltd, 2022
Acromegaly – Pipeline by Aquestive Therapeutics Inc, 2022
Acromegaly – Pipeline by ASCIL Biopharm, 2022
Acromegaly – Pipeline by Camurus AB, 2022
Acromegaly – Pipeline by Crinetix Pharmaceuticals Inc, 2022
Acromegaly – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Acromegaly – Pipeline by Debiopharm International SA, 2022
Acromegaly – Pipeline by DexTech Medical AB, 2022
Acromegaly – Pipeline by Enesi Pharma Ltd, 2022
Acromegaly – Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
Acromegaly – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Acromegaly – Pipeline by Genevant Sciences Ltd, 2022
Acromegaly – Pipeline by GlyTech Inc, 2022
Acromegaly – Pipeline by Ionis Pharmaceuticals Inc, 2022
Acromegaly – Pipeline by Italfarmaco SpA, 2022
Acromegaly – Pipeline by OPKO Health Inc, 2022
Acromegaly – Pipeline by Pharmathen Global BV, 2022
Acromegaly – Pipeline by Rani Therapeutics LLC, 2022
Acromegaly – Pipeline by Strongbridge Biopharma plc, 2022
Acromegaly – Dormant Projects, 2022
Acromegaly – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acromegaly, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A9C1473E3ABBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9C1473E3ABBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

